Prospective assessment of a gene signature potentially predictive of clinical benefit in metastatic melanoma patients following MAGE-A3 immunotherapeutic (PREDICT).
about
Prospective assessment of a gene signature potentially predictive of clinical benefit in metastatic melanoma patients following MAGE-A3 immunotherapeutic (PREDICT).
description
article científic
@ca
article scientifique
@fr
articolo scientifico
@it
artigo científico
@pt
bilimsel makale
@tr
scientific article published on 08 August 2016
@en
vedecký článok
@sk
vetenskaplig artikel
@sv
videnskabelig artikel
@da
vědecký článek
@cs
name
Prospective assessment of a ge ...... 3 immunotherapeutic (PREDICT).
@en
Prospective assessment of a ge ...... wing MAGE-A3 immunotherapeutic
@nl
type
label
Prospective assessment of a ge ...... 3 immunotherapeutic (PREDICT).
@en
Prospective assessment of a ge ...... wing MAGE-A3 immunotherapeutic
@nl
prefLabel
Prospective assessment of a ge ...... 3 immunotherapeutic (PREDICT).
@en
Prospective assessment of a ge ...... wing MAGE-A3 immunotherapeutic
@nl
P2093
P2860
P50
P356
P1433
P1476
Prospective assessment of a ge ...... A3 immunotherapeutic (PREDICT)
@en
P2093
A Hauschild
C Vanden Abeele
P2860
P304
P356
10.1093/ANNONC/MDW291
P577
2016-08-08T00:00:00Z